title: Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis.
abstract: The objective of this study was to evaluate the association between antimonial therapy and circulating levels of proinflammatory cytokines in patients with cutaneous leishmaniasis (CL). Patients were treated with conventional chemotherapy by using pentavalent antimonium salts (Glucantime) for 3 weeks. Circulating plasma levels of the proinflammatory cytokines interleukin-1beta (IL-1beta), IL-6, IL-8, and tumor necrosis factor alpha (TNF-alpha) were determined for CL patients and healthy subjects before and 3 weeks after the treatment was started. Plasma IL-1beta, IL-6, IL-8, and TNF-alpha levels were significantly higher for pretreatment CL patients than for healthy subjects. Proinflammatory cytokines significantly increased after 21 days postinfection compared to levels for the pretreatment patients. These increments were approximately 3-fold for IL-1beta and TNF-alpha levels, 10-fold for IL-6 levels, and 20-fold for IL-8 levels in patients with CL. Taken together these results indicate that circulating proinflammatory cytokine levels were increased in patients with CL as a consequence of host defense strategies, and antimonial therapy may induce these cytokines by affecting the macrophage or other components of the host defense system.
authors.affiliation: Department of Biochemistry, University of Harran Medical School, Sanliurfa 63200, Turkey. kocyigit30@hotmail.com
authors.forename: Abdurrahim
authors.initials: A
authors.lastname: Kocyigit
authors.forename: Selahaddin
authors.initials: S
authors.lastname: Gur
authors.forename: Mehmet S
authors.initials: MS
authors.lastname: Gurel
authors.forename: Vedat
authors.initials: V
authors.lastname: Bulut
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ulukanligil
mesh_terms: D000293:Adolescent; D000328:Adult; D000965:Antimony; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002648:Child; D016207:Cytokines / Q000097:blood*; D006801:Humans; D007249:Inflammation / Q000097:blood*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D016207:Cytokines; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony